Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at HC Wainwright from $6.50 to $5.00. They now have a "buy" rating on the stock.
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab [Yahoo! Finance]
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? [Yahoo! Finance]
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers [Yahoo! Finance]